Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | USP47 | Q96K76 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 3/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.36 |
| ▸ | USP7 | Q93009 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11259653 | 0.84 | USP47 (0.52) | USP47GPR35MEN1ALDH1A1KMT2A | |
| SCHEMBL3880847 | 0.83 | USP10 (0.47) | TSHRLMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL3230116 | 0.79 | CA1 (0.43) | CA1CA2CASP6USP47TSHR | |
| SCHEMBL1456043 | 0.78 | DAO (0.55) | CA1CA2CASP6USP47TSHR | |
| SCHEMBL1242736 | 0.78 | DAO (0.55) | CA1CA2CASP6USP47TSHR | |
| SCHEMBL3878737 | 0.76 | USP10 (0.56) | LMNAKDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL6508901 | 0.74 | DAO (0.38) | CA1CA2CASP6DAOGPR35 | |
| SCHEMBL2680731 | 0.74 | CYP3A4 (0.39) | TSHRLMNAGPR35KDM4EMEN1 | |
| SCHEMBL19433701 | 0.74 | PTPN2 (0.51) | CA1CA2CASP6LMNAGPR35 | |
| SCHEMBL31158466 | 0.74 | PTPN2 (0.51) | CA1CA2CASP6LMNAGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4225288-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076589-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-4211696-A | Disperse monoazo dyestuffs derived from 3,5-dinitro-2-amino thiophene as disazo component and an arylamine coupling component | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | CA1 3193/4885CA2 2566/4885CASP6 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.